Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New and future migraine therapy.

Nabih M Ramadan1, Thomas M Buchanan

  • 1Department of Neurology, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA. nabih.ramadan@rosalindfranklin.edu

Pharmacology & Therapeutics
|June 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Unmet Challenge of Diagnosing and Treating Photophobia.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022
Same author

Ocular and Cervical Vestibular Evoked Myogenic Potentials in Patients With Vestibular Migraine.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2018
Same author

Glutamate and migraine: from Ikeda to the 21st century.

Cephalalgia : an international journal of headache·2013
Same author

Commentary on headache currents articles by Alhazzani and Goddeau.

Headache·2013
Same author

Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism.

Headache·2009
Same author

Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.

Headache·2008
Same journal

Protein acetylation modification in tissue fibrosis: Opportunities and challenges.

Pharmacology & therapeutics·2026
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
See all related articles

Advances in neuroscience have improved acute migraine treatments, but novel preventive therapies are still needed. Future research focusing on genetic predispositions and biomarkers may uncover new targets for effective migraine prevention.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Modern neuroscience has enhanced understanding of migraine mechanisms, leading to improved acute treatments like triptans (5-HT1B,D agonists).
  • Current migraine prevention strategies rely on repurposed drugs, highlighting an unmet need for novel, mechanism-based preventive therapies.

Purpose of the Study:

  • To review advancements in acute migraine therapeutics.
  • To highlight the lack of novel therapeutic targets for migraine prevention.
  • To discuss future directions for developing mechanism-based preventive migraine drugs.

Main Methods:

  • Review of scientific literature on migraine pathophysiology and therapeutics.
  • Analysis of current trends in drug discovery for migraine.

Main Results:

Related Experiment Videos

  • Significant progress has been made in acute migraine treatment with drugs targeting serotonin receptors, CGRP, glutamatergic receptors, and nitric oxide synthase.
  • Novel targets for migraine prevention remain scarce, with current prophylactic treatments being repurposed from other indications.

Conclusions:

  • While acute migraine therapies have advanced, there is a critical need for new preventive treatments.
  • Future research into genetic factors, biomarkers, and preclinical models is essential for identifying novel, mechanism-based targets for migraine prevention.